A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated

Yuh Min Chen, Reury Perng Perng, Jen Fu Shih, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Phase II studies have suggested that vinorelbine (V) plus gemcitabine (G) treatment has a similar response rate and better toxicity profile than cisplatin-based combination chemotherapy in non-small-cell lung cancer (NSCLC). Our aim was to evaluate whether or not the addition of cisplatin (P) to a VG regimen increases the efficacy or toxicities in chemo-naïve inoperable NSCLC patients. From April 2002 to October 2003, 86 patients were enrolled. The treatment dose was V 20 mg/m2 plus G 800 mg/m2 intravenous infusion (IV) on days 1, 8 and 15, with/without P 60 mg/m2 IV on day 15, every 4 weeks. The efficacy and toxicity of the treatment were recorded. In all, 125 cycles of VG and 178 cycles of VGP were given to the patients in the VG and VGP arms, respectively (P = 0.001). The median cycle of treatment was three in the VG arm and five in the VGP arm. There were 10 partial responses (overall 23.3%) in the VG arm and 1 complete response and 19 partial responses (overall 46.5%) in the VGP arm (P = 0.022). Neutropenia, nausea, vomiting, and peripheral neuropathy were more common in the VGP arm (P = 0.023, 0.002, 0.025, 0.001, respectively). The Lung Cancer Symptom Scale showed no difference between the VG and VGP arms after two cycles of treatment or when the patient went off study. We concluded that the addition of P to VG treatment did increase both the tumor response rate and the toxicities. However, the toxicities were tolerable.

Original languageEnglish
Pages (from-to)373-380
Number of pages8
JournalLung Cancer
Volume47
Issue number3
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Intravenous Infusions
Therapeutics
Peripheral Nervous System Diseases
Combination Drug Therapy
Neutropenia
Nausea
Vomiting
Lung Neoplasms
vinorelbine

Keywords

  • Cisplatin
  • Gemcitabine
  • Non-small-cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. / Chen, Yuh Min; Perng, Reury Perng; Shih, Jen Fu; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 47, No. 3, 01.01.2005, p. 373-380.

Research output: Contribution to journalArticle

@article{8311803d932c4052be9998d7c952b9ac,
title = "A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated",
abstract = "Phase II studies have suggested that vinorelbine (V) plus gemcitabine (G) treatment has a similar response rate and better toxicity profile than cisplatin-based combination chemotherapy in non-small-cell lung cancer (NSCLC). Our aim was to evaluate whether or not the addition of cisplatin (P) to a VG regimen increases the efficacy or toxicities in chemo-na{\"i}ve inoperable NSCLC patients. From April 2002 to October 2003, 86 patients were enrolled. The treatment dose was V 20 mg/m2 plus G 800 mg/m2 intravenous infusion (IV) on days 1, 8 and 15, with/without P 60 mg/m2 IV on day 15, every 4 weeks. The efficacy and toxicity of the treatment were recorded. In all, 125 cycles of VG and 178 cycles of VGP were given to the patients in the VG and VGP arms, respectively (P = 0.001). The median cycle of treatment was three in the VG arm and five in the VGP arm. There were 10 partial responses (overall 23.3{\%}) in the VG arm and 1 complete response and 19 partial responses (overall 46.5{\%}) in the VGP arm (P = 0.022). Neutropenia, nausea, vomiting, and peripheral neuropathy were more common in the VGP arm (P = 0.023, 0.002, 0.025, 0.001, respectively). The Lung Cancer Symptom Scale showed no difference between the VG and VGP arms after two cycles of treatment or when the patient went off study. We concluded that the addition of P to VG treatment did increase both the tumor response rate and the toxicities. However, the toxicities were tolerable.",
keywords = "Cisplatin, Gemcitabine, Non-small-cell lung cancer, Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Shih, {Jen Fu} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.lungcan.2004.08.007",
language = "English",
volume = "47",
pages = "373--380",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Shih, Jen Fu

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Phase II studies have suggested that vinorelbine (V) plus gemcitabine (G) treatment has a similar response rate and better toxicity profile than cisplatin-based combination chemotherapy in non-small-cell lung cancer (NSCLC). Our aim was to evaluate whether or not the addition of cisplatin (P) to a VG regimen increases the efficacy or toxicities in chemo-naïve inoperable NSCLC patients. From April 2002 to October 2003, 86 patients were enrolled. The treatment dose was V 20 mg/m2 plus G 800 mg/m2 intravenous infusion (IV) on days 1, 8 and 15, with/without P 60 mg/m2 IV on day 15, every 4 weeks. The efficacy and toxicity of the treatment were recorded. In all, 125 cycles of VG and 178 cycles of VGP were given to the patients in the VG and VGP arms, respectively (P = 0.001). The median cycle of treatment was three in the VG arm and five in the VGP arm. There were 10 partial responses (overall 23.3%) in the VG arm and 1 complete response and 19 partial responses (overall 46.5%) in the VGP arm (P = 0.022). Neutropenia, nausea, vomiting, and peripheral neuropathy were more common in the VGP arm (P = 0.023, 0.002, 0.025, 0.001, respectively). The Lung Cancer Symptom Scale showed no difference between the VG and VGP arms after two cycles of treatment or when the patient went off study. We concluded that the addition of P to VG treatment did increase both the tumor response rate and the toxicities. However, the toxicities were tolerable.

AB - Phase II studies have suggested that vinorelbine (V) plus gemcitabine (G) treatment has a similar response rate and better toxicity profile than cisplatin-based combination chemotherapy in non-small-cell lung cancer (NSCLC). Our aim was to evaluate whether or not the addition of cisplatin (P) to a VG regimen increases the efficacy or toxicities in chemo-naïve inoperable NSCLC patients. From April 2002 to October 2003, 86 patients were enrolled. The treatment dose was V 20 mg/m2 plus G 800 mg/m2 intravenous infusion (IV) on days 1, 8 and 15, with/without P 60 mg/m2 IV on day 15, every 4 weeks. The efficacy and toxicity of the treatment were recorded. In all, 125 cycles of VG and 178 cycles of VGP were given to the patients in the VG and VGP arms, respectively (P = 0.001). The median cycle of treatment was three in the VG arm and five in the VGP arm. There were 10 partial responses (overall 23.3%) in the VG arm and 1 complete response and 19 partial responses (overall 46.5%) in the VGP arm (P = 0.022). Neutropenia, nausea, vomiting, and peripheral neuropathy were more common in the VGP arm (P = 0.023, 0.002, 0.025, 0.001, respectively). The Lung Cancer Symptom Scale showed no difference between the VG and VGP arms after two cycles of treatment or when the patient went off study. We concluded that the addition of P to VG treatment did increase both the tumor response rate and the toxicities. However, the toxicities were tolerable.

KW - Cisplatin

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=13844298523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844298523&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.08.007

DO - 10.1016/j.lungcan.2004.08.007

M3 - Article

VL - 47

SP - 373

EP - 380

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -